| 1 |
30405170 | Scaffold-Hopping from Synthetic Drugs by Holistic Molecular Representation. | 2018 Nov 7 |
1 |
| 2 |
30422238 | Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. | 2018 Dec 1 |
3 |
| 3 |
27320328 | Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. | 2017 |
1 |
| 4 |
26822146 | Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. | 2016 Jan 29 |
1 |
| 5 |
27297672 | The Effect of the APOE4 Gene on Accumulation of Aβ40 After Brain Injury Cannot Be Reversed by Increasing apoE4 Protein. | 2016 Aug |
3 |
| 6 |
27567858 | ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. | 2016 Oct 4 |
3 |
| 7 |
29067298 | A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects. | 2016 Jun |
8 |
| 8 |
24664180 | Brain metabolite clearance: impact on Alzheimer's disease. | 2014 Sep |
2 |
| 9 |
24849361 | Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. | 2014 May 21 |
5 |
| 10 |
25217640 | Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. | 2014 Oct 31 |
2 |